Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Journal
International Journal of Infectious Diseases
Journal Volume
92
Pages
71-77
Date Issued
2020
Author(s)
Abstract
Objective: To evaluate the evolution of weight and lipid profiles before and after switch to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) among virally suppressed HIV-positive patients. Methods: Patients switching to E/C/F/TAF between March and July 2018 were included. Weight, lipid profile (triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C)), and glycated hemoglobin (HbA1c) levels at 48 weeks before and after the switch were analyzed using generalized estimating equations in order to identify the associated factors. Results: A total of 693 patients were included, and a weight gain was noted after the switch at weeks 12 (mean +0.63 kg), 24 (+1.25), 36 (+1.58), and 48 (+1.75) (all p < 0.0001). The weight change after the switch was significantly greater than that observed within the preceding 48-week period before the switch (+1.75 kg vs +0.54, p < 0.0001) and was correlated with switch to E/C/F/TAF (coefficient 0.29), later clinic visit (0.15), baseline weight (0.99), diabetes mellitus (coefficient ?0.96), and age (?0.02) (all p < 0.01). At week 48, significant increases were observed for TG (mean +62.93 mg/dl), TC (+22.30), LDL-C (+9.70), HDL-C (+3.65) (all p < 0.01), and HbA1c (+0.08%) (p < 0.05), but not TC/HDL-C ratio (+0.12, p = 0.38). Conclusions: Virally suppressed HIV-positive patients gained a moderate amount of weight and had significant increases in lipid levels after switching to E/C/F/TAF. ? 2019 The Author(s)
SDGs
Other Subjects
abacavir plus dolutegravir plus lamivudine; cholesterol; cobicistat plus elvitegravir plus emtricitabine plus tenofovir alafenamide; efavirenz plus emtricitabine plus tenofovir disoproxil; emtricitabine plus rilpivirine plus tenofovir disoproxil; glucose; hemoglobin A1c; high density lipoprotein cholesterol; low density lipoprotein cholesterol; tenofovir disoproxil; triacylglycerol; virus RNA; adenine; anti human immunodeficiency virus agent; cobicistat; elvitegravir; emtricitabine; GS-7340; lipid; quinolone derivative; adult; antiretroviral therapy; art; Article; body mass; body weight change; body weight gain; CD4 lymphocyte count; cholesterol blood level; cohort analysis; diabetes mellitus; drug substitution; drug withdrawal; dyslipidemia; female; glucose blood level; hemoglobin blood level; human; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; lipid fingerprinting; major clinical study; male; men who have sex with men; observational study; retrospective study; side effect; treatment duration; triacylglycerol blood level; virus load; blood; complication; dyslipidemia; highly active antiretroviral therapy; Human immunodeficiency virus infection; middle aged; virology; Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Dyslipidemias; Emtricitabine; Female; HIV Seropositivity; Humans; Lipids; Male; Middle Aged; Quinolones; Retrospective Studies; Weight Gain
Publisher
Elsevier B.V.
Type
journal article